Open Orphan Plc (OPORF)
| Previous close | 0.2300 |
| Open | 0.2300 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.2300 - 0.2300 |
| 52-week range | 0.2300 - 0.5600 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 154.314M |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafterOCALA, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:AIM) today announced that AIM and hVIVO have a signed Clinical Trial Agreement (CTA) for a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal prophylactic using a human rhinovirus (H
- GlobeNewswire
AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy
Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen’s effectiveness against those, and potentially other virusesOCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rhin
